Genomics Investment Boosts US Economy

A new analysis suggests that the Human Genome Project has delivered $178 for every federal dollar invested, but many analysts are not convinced by the figures.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, 401(K) 2013A report released yesterday (June 12) claims that for every public dollar invested in the Human Genome Project (HGP), the US economy has benefitted to the tune of $178—and that the total economic boost from the HGP and subsequent federal investment in genomics stands at $965 billion. But many analysts are not convinced by those figures, arguing that they ignore other sources of investment in genomics and thus attribute too much impact to government spending on genomics research. Other critics pointed out the HGP should be judged not on how much economic activity it generated, but on its impact on human health.

The analysis was done on behalf of advocacy group United for Medical Research by the Battelle Memorial Institute, which in 2010 calculated a return of $141 per dollar from the HGP. Battelle used an “input-output” economic analysis—the input was the government’s initial investment, while the output was money generated by genomics-related business and university research, including the value of goods produced, incomes taxes, and the personal incomes of people employed in the genomics sector. The results suggest the economic impact of the project and related investment in genomics research continues to grow.

But critics of the report cited several problems. Speaking to Nature, Julia Lane, an economist at the American Institutes for Research in Washington D.C., described the numbers as “ridiculous.” She said that Battelle ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies